206181-63-7

206181-63-7 structure

Name: ibritumomab tiuxetan
Chemical Name: Ibritumomab
CAS Number: 206181-63-7
Molecular Formula: C₂₄H₃₅N₅O₁₁
Molecular Weight: 569.562
Catalog: Research Areas Cancer
Create Date: 2018-07-01 01:01:15
Modify Date: 2024-01-11 19:52:23
Ibritumomab tiuxetan is an immunoconjugate composed of the murine IgG1κ anti-CD20 monoclonal antibody Ibritumomab that is covalently bound to the chelator Tiuxetan that permits the addition of the short-lived β-emitter radioisotope yttrium-90. Ibritumomab tiuxetan can be used for the research of non-Hodgkin's B-cell lymphomas[1][2].

Name	Ibritumomab
Synonyms	Ibritumomab N-[(2S)-2-[Bis(carboxymethyl)amino]-3-(4-{[hydroxy(methylimino)methyl]amino}phenyl)propyl]-N-{2-[bis(carboxymethyl)amino]propyl}glycine

Description	Ibritumomab tiuxetan is an immunoconjugate composed of the murine IgG1κ anti-CD20 monoclonal antibody Ibritumomab that is covalently bound to the chelator Tiuxetan that permits the addition of the short-lived β-emitter radioisotope yttrium-90. Ibritumomab tiuxetan can be used for the research of non-Hodgkin's B-cell lymphomas[1][2].
Related Catalog	Research Areas >> Cancer
Target	CD20sup>[1]
In Vitro	Ibritumomab 和 Tiuxetan 通过共价硫脲键结合。Tiuxetan 为两种放射性物质 Indium-111 (In-111) 和 Yttrium-90 (Y-90) 提供了一个限制螯合位点。
References	[1]. Mukherjee S, et, al. Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA). Hematol Oncol Stem Cell Ther. 2018 Sep;11(3):187-188. [2]. Johnston PB, et, al. Ibritumomab tiuxetan for non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006 Jun;6(6):861-9.